The evolving aml genomic landscape: Therapeutic implications

Sachi Horibata*, George Alyateem, Christin B. Destefano, Michael M. Gottesman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Improved understanding of the genomic and molecular landscape of acute myeloid leukemia (AML) has resulted in a significant evolution of our understanding of AML biology and al-lows refined prognostication for those receiving standard combination chemotherapy induction. This dramatic increase in knowledge preceded, and was somewhat responsible for, at least some of eight new FDA drug approvals for AML. This review discusses the impact of genomics on clinical care of AML patients and highlights newly approved FDA drugs. Despite these recent clinical advances, however, the outcome for most patients diagnosed with AML remains dire. Thus, we describe here some of the challenges identified with treating AML including off-target toxicity, drug transporters, clonal heterogeneity, and adaptive resistance, and some of the most promising opportunities for improved therapy.

Original languageEnglish
Pages (from-to)532-544
Number of pages13
JournalCurrent Cancer Drug Targets
Issue number7
StatePublished - 2020
Externally publishedYes


  • Acute myeloid leukemia (AML)
  • Clinical implications
  • Drug transporters
  • Genomic landscape
  • Hematologic malignancy
  • Therapeutics


Dive into the research topics of 'The evolving aml genomic landscape: Therapeutic implications'. Together they form a unique fingerprint.

Cite this